Role of the adaptor protein LNK in normal and malignant hematopoiesis

Oncogene

Volumn 32, Issue 26, 2013, Pages 3111-3118

  Gery, S ^a   Koeffler, H P ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

cytokine signaling; hematopoiesis; LNK

Indexed keywords

ADAPTOR PROTEIN; CD135 ANTIGEN; CYTOKINE; ERYTHROPOIETIN; JANUS KINASE 2; NERVE GROWTH FACTOR; PROTEIN LNK; STEM CELL FACTOR; THROMBOPOIETIN; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL DIFFERENTIATION; CELL EXPANSION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CYTOKINE PRODUCTION; GENE SEQUENCE; GENE THERAPY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; HUMAN; LEUKEMIA; MYELOPROLIFERATIVE NEOPLASM; NEGATIVE FEEDBACK; NONHUMAN; PRE T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC MASTOCYTOSIS;

ANIMALS; AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; CELL DIFFERENTIATION; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HUMANS; MICE; MYELOPROLIFERATIVE DISORDERS; PROTEIN INTERACTION MAPS; PROTEIN-TYROSINE KINASES; PROTEINS; SIGNAL TRANSDUCTION;

ANIMALIA; MURINAE; MUS;

EID: 84879696421     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.435     Document Type: Review

References (73)

1. Toffalini F, Demoulin JB. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood. 2010; 116: 2429-2437.
2. Jatiani SS, Baker SJ, Silverman LR, Reddy EP. Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer 2010; 1: 979-993.
3. Takaki S, Morita H, Tezuka Y, Takatsu K. Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. J Exp Med 2002; 195: 151-160.
4. Velazquez L, Cheng AM, Fleming HE, Furlonger C, Vesely S, Bernstein A et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med 2002; 195: 1599-1611.
5. Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs Jr KD et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010; 116: 988-992.
6. Oh ST, Zahn JM, Jones CD, Zhang B, Loh ML, Kantarjian HM et al. Identification of novel LNK mutations in patients with chronic myeloproliferative neoplasms and related disorders. Blood 2010; 116: (abstract 315).
7. Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi ALNK. mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010; 24: 1713-1718.
8. Lasho TL, Pardanani A, Tefferi ALNK. mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 2010; 363: 1189-1190.
9. Baran-Marszak F, Magdoud H, Desterke C, Alvarado A, Roger C, Harel S et al. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms. Blood 2010; 116: 5961-5971.
10. Lasho TL, Tefferi A, Finke C, Pardanani A. Clonal hierarchy and allelic mutation segregation in a myelofibrosis patient with two distinct LNK mutations. Leukemia 2011; 25: 1056-1058.
11. Hurtado C, Erquiaga I, Aranaz P, Migueliz I, Garcia-Delgado M, Novo FJ et al. LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation. Leuk Res 2011; 35: 1537-1539.
12. Ha JS, Jeon DS. Possible new LNK mutations in myeloproliferative neoplasms. Am J Hematol 2011; 86: 866-868.
13. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukemia. Nature 2012; 481: 157-163.
14. Dhe-Paganon S, Werner ED, Nishi M, Hansen L, Chi YI, Shoelson SE. A phenylalanine zipper mediates APS dimerization. Nat Struct Mol Biol 2004; 11: 968-974.
15. Maures TJ, Kurzer JH, Carter-Su C. SH2B1 (SH2-B) and JAK2: a multifunctional adaptor protein and kinase made for each other. Trends Endocrinol Metab 2007; 18: 38-45.
16. Devalliere J, Charreau B. The adaptor Lnk (SH2B3): an emerging regulator in vascular cells and a link between immune and inflammatory signaling. Biochem Pharmacol 2011; 15: 1391-1402.
17. Morris DL, Cho KW, Rui L. Critical role of the Src homology 2 (SH2) domain of neuronal SH2B1 in the regulation of body weight and glucose homeostasis in mice. Endocrinology 2010; 151: 3643-3651.
18. Li M, Ren D, Iseki M, Takaki S, Rui L. Differential role of SH2-B and APS in regulating energy and glucose homeostasis. Endocrinology 2006; 147: 2163-2170.
19. Huang X, Li Y, Tanaka K, Moore KG, Hayashi JI. Cloning and characterization of Lnk, a signal transduction protein that links T-cell receptor activation signal to phospholipase C gamma 1, Grb2, and phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA 1995; 92: 11618-11622.
20. Ema H, Sudo K, Seita J, Matsubara A, Morita Y, Osawa M et al. Quantification of self-renewal capacity in single hematopoietic stem cells from normal and Lnk-deficient mice. Dev Cell 2005; 8: 907-914.
21. Takizawa H, Kubo-Akashi C, Nobuhisa I, Kwon SM, Iseki M, Taga T et al. Enhanced engraftment of hematopoietic stem/progenitor cells by the transient inhibition of an adaptor protein, Lnk. Blood 2006; 107: 2968-2975.
22. Buza-Vidas N, Antonchuk J, Qian H, Mansson R, Luc S, Zandi S et al. Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK. Genes Dev 2006; 20: 2018-2023.
23. Seita J, Ema H, Ooehara J, Yamazaki S, Tadokoro Y, Yamasaki A et al. Lnk negatively regulates self-renewal of hematopoietic stem cells by modifying thrombopoietinmediated signal transduction. Proc Natl Acad Sci USA 2007; 104: 2349-2354.
24. Bersenev A, Wu C, Balcerek J, Tong W. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J Clin Invest 2008; 118: 2832-2844.
25. Tong W, Zhang J, Lodish HF. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 2005; 105: 4604-4612.
26. Tong W, Lodish HF. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J Exp Med 2004; 200: 569-580.
27. Takizawa H, Nishimura S, Takayama N, Oda A, Nishikii H, Morita Y et al. Lnk regulates integrin alphaIIbbeta3 outside-in signaling in mouse platelets, leading to stabilization of thrombus development in vivo. J Clin Invest 2010; 120: 179-190.
28. Takizawa H, Eto K, Yoshikawa A, Nakauchi H, Takatsu K, Takaki S. Growth and maturation of megakaryocytes is regulated by Lnk/Sh2b3 adaptor protein through crosstalk between cytokine- and integrin-mediated signals. Exp Hematol 2008; 36: 897-906.
29. Simon C, Dondi E, Chaix A, de Sepulveda P, Kubiseski TJ, Varin-Blank N et al. Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells. Blood 2008; 112: 4039-4047.
30. Gueller S, Goodridge HS, Niebuhr B, Xing H, Koren-Michowitz M, Serve H et al. Adaptor protein Lnk inhibits c-Fms-mediated macrophage function. J Leukoc Biol 2010; 88: 699-706.
31. Nobuhisa I, Takizawa M, Takaki S, Inoue H, Okita K, Ueno M et al. Regulation of hematopoietic development in the aorta-gonad-mesonephros region mediated by Lnk adaptor protein. Mol Cell Biol 2003; 23: 8486-8494.
32. Wan M, Li Y, Xue H, Li Q, Li J. TNF alpha induces Lnk expression through PI3K-dependent signaling pathway in human umbilical vein endothelial cells. J Surg Res 2006; 136: 535-537.
33. Devalliere J, Chatelais M, Fitau J, Gerard N, Hulin P, Velazquez L et al. LNK (SH2B3) is a key regulator of integrin signaling in endothelial cells and targets a-parvin to control cell adhesion and migration 2012; 26: 2592-2606.
34. Kwon SM, Suzuki T, Kawamoto A, Ii M, Eguchi M, Akimaru H et al. Pivotal role of lnk adaptor protein in endothelial progenitor cell biology for vascular regeneration. Circ Res 2009; 104: 969-1077.
35. Kamei N, Kwon SM, Alev C, Ishikawa M, Yokoyama A, Nakanishi K et al. Lnk deletion reinforces the function of bone marrow progenitors in promoting neovascularization and astrogliosis following spinal cord injury. Stem Cells 2010; 28: 365-375.
36. Matsumoto T, Ii M, Nishimura H, Shoji T, Mifune Y, Kawamoto A et al. Lnk-dependent axis of SCF-cKit signal for osteogenesis in bone fracture healing. J Exp Med 2010; 207: 2207-2223.
37. Kurzer JH, Saharinen P, Silvennoinen O, Carter-Su C. Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active state. Mol Cell Biol 2006; 26: 6381-6394.
38. Gery S, Cao Q, Gueller S, Xing H, Tefferi A, Koeffler HP. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J Leukoc Biol 2009; 85: 957-965.
39. Jiang J, Balcerek J, Rozenova K, Cheng Y, Bersenev A, Wu C et al. 14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cells. J Clin Invest 2012 59719122: 2079-91.
40. Gueller S, Gery S, Nowak V, Liu L, Serve H, Koeffler HP. Adaptor protein Lnk associates with Tyr(568) in c-Kit. Biochem J 2008; 415: 241-245.
41. Gueller S, Hehn S, Nowak V, Gery S, Serve H, Brandts CH et al. Adaptor protein Lnk binds to PDGF receptor and inhibits PDGF-dependent signaling. Exp Hematol 2011; 39: 591-600.
42. Lin DC, Yin T, Koren-Michowitz M, Ding LW, Gueller S, Gery S et al. Adaptor protein Lnk binds to and inhibits normal and leukemic Flt3. Blood (e-pub ahead of print 31 August 2012).
43. Wang TC, Chiu H, Chang YJ, Hsu TY, Chiu IM, Chen L. The adaptor protein SH2B3 (Lnk) negatively regulates neurite outgrowth of PC12 cells and cortical neurons. PLoS One 2011; 6: e26433.
44. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
45. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011; 29: 573-582.
46. Gery S, Gueller S, Chumakova K, Kawamata N, Liu L, Koeffler HP. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood 2007; 110: 3360-3364.
47. Koren-Michowitz M, Gery S, Nowak D, Nagler A, Matsubara A, Tabayashi T et al. Adaptor protein LNK binds to and is phosphorylated by JAK3 and may serve as a scaffold for JAK3 autophosphorylation in the absence of an appropriate cytokine receptor. Blood 2010; 116: (abstract 315).
48. Gery S, Gueller S, Nowak V, Sohn J, Hofmann WK, Koeffler HP. Expression of the adaptor protein Lnk in leukemia cells. Exp Hematol 2009; 37: e2.
49. Bersenev A, Wu C, Balcerek J, Jing J, Kundu M, Blobel GA et al. Lnk constrains myeloproliferative diseases in mice. J Clin Invest 2010; 120: 2058-2069.
50. Koren-MichowitzM Gery S, Tabyashi T, Lin D, Nagler A, Koeffler HP. The Lnk PH domain point mutations found in patients with MPN are mild partial loss of function mutations with a variable inhibitory effect on WT JAK2 and JAK2 V617F. Haematologica.
51. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274.
52. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
53. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012; 485: 502-506.
54. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007; 39: 857-864.
55. Smyth DJ, Plagnol V, Walker NM, Cooper JD, Downes K, Yang JH et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med 2008; 359: 2767-2777.
56. Hunt KA, Zhernakova A, Turner G, Heap GA, Franke L, Bruinenberg M et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 2008; 40: 395-402.
57. Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009; 41: 1228-1233.
58. Coenen MJ, Trynka G, Heskamp S, Franke B, Van Diemen CC, Smolonska J et al. Common and different genetic background for rheumatoid arthritis and coeliac disease. Hum Mol Genet 2009; 18: 4195-4203.
59. Alcina A, Vandenbroeck K, Otaegui D, Saiz A, Gonzalez JR, Fernandez O et al. The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis. Genes Immun 2010; 11: 439-445.
60. Eriksson N, Tung JY, Kiefer AK, Hinds DA, Francke U, Mountain JL et al. Novel associations for hypothyroidism include known autoimmune risk loci. PLoS One 2012; 7: e34442.
61. Jin Y, Birlea SA, Fain PR, Ferrara TM, Ben S, Riccardi SL et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet 2012; 44: 676-680.
62. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 2009; 41: 677-687.
63. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L et al. Genomewide association study identifies eight loci associated with blood pressure. Nat Genet 2009; 41: 666-676.
64. Gudbjartsson DF, Bjornsdottir US, Halapi E, Helgadottir A, Sulem P, Jonsdottir GM et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet 2009; 41: 342-347.
65. Lavrikova EY, Nikitin AG, Kuraeva TL, Peterkova VA, Tsitlidze NM, Chistiakov DA et al. The carriage of the type 1 diabetes-associated R262W variant of human LNK correlates with increased proliferation of peripheral blood monocytes in diabetic patients. Pediatr Diabetes 2011; 12: 127-132.
66. Zhernakova A, Elbers CC, Ferwerda B, Romanos J, Trynka G, Dubois PC et al. Evolutionary and functional analysis of celiac risk loci reveals SH2B3 as a protective factor against bacterial infection. Am J Hum Genet 2010; 86: 970-977.
67. McMullin MF, Wu C, Percy MJ, Tong W. A nonsynonymous LNK polymorphism associated with idiopathic erythrocytosis. Am J Hematol 2011; 86: 962-964.
68. Looi CY, Imanishi M, Takaki S, Sato M, Chiba N, Sasahara Y et al. Octa-arginine mediated delivery of wild-type Lnk protein inhibits TPO-induced M-MOK megakaryoblastic leukemic cell growth by promoting apoptosis. PLoS One 2011; 6: e23640.
69. Dravid G, Zhu Y, Scholes J, Evseenko D, Crooks GM. Dysregulated gene expression during hematopoietic differentiation from human embryonic stem cells. Mol Ther 2011; 19: 768-781.
70. Ahlenius H, Devaraju K, Monni E, Oki K, Wattananit S, Darsalia V et al. Adaptor protein LNK is a negative regulator of brain neural stem cell proliferation after stroke. J Neurosci 2012; 11: 5151-5164.
71. Hu J, Hubbard SR. Structural characterization of a novel Cbl phosphotyrosine recognition motif in the APS family of adapter proteins. J Biol Chem 2005; 280: 18943-18949.
72. Li Y, He X, Schembri-King J, Jakes S, Hayashi J. Cloning and characterization of human Lnk, an adaptor protein with pleckstrin homology and Src homology 2 domains that can inhibit T cell activation. J Immunol 2000; 164: 5199-51206.
73. He X, Li Y, Schembri-King J, Jakes S, Hayashi J. Identification of actin binding protein, ABP-280, as a binding partner of human Lnk adaptor protein. Mol Immunol 2000; 37: 603-612.